Dissemination (Spotlight)

Due to the critical nature of acute HF (AHF), accurately gauging the risk for mortality may help...

Iron deficiency is a widely prevalent finding in patients with heart failure, observed on average...

Men with metastatic hormone-sensitive prostate cancer who experience baseline bone pain have worse survival outcomes despite treatment intensification.

Various sessions at the 2024 ASCO Genitourinary Cancers Symposium reviewed health care discrimination and disparities among patients with prostate cancer.

Researchers emphasized the importance of bone-protective agents in patients treated for metastatic castration-resistant prostate cancer.

Researchers found correlations between PSMA PET total tumor burden and survival in patients with high-volume metastatic hormone-sensitive prostate cancer.

The following is a summary of “Effectiveness of Aspirin on Major COPD Outcomes: A Prevalent...

The following is a summary of “Impressions and Perceptions of a Smartphone and Smartwatch...

The following is a summary of “Respiratory Oscillometry and Functional Performance in Different...

Several clinical trials have tested the efficacy and safety of valbenazine and deutetrabenazine in patients with TD.

The following is a summary of “High Blood Eosinophil Count at Stable State is Not Associated with...

The following is a summary of “Automated Quantification of QT-Intervals by an Algorithm: A...

Emerging evidence underscores the significant impact of diet on IBD development and treatment.

Deep brain stimulation offers advantages such as adjustability, reversibility, and the potential for rapid and long-term improvement in tardive dyskinesia.

Targeted microbiota manipulation using probiotics, prebiotics, synbiotics, and fecal microbiota transplantation holds potential for IBD treatment.

Annual training and reliable new tools can help physicians improve tardive dyskinesia screening and symptom measurement.

Patients with inflammatory bowel diseases often experience insomnia and various mental health conditions that healthcare providers should monitor.

Advances in the management of IBD may support a shift from hospital-based care to community-based care.

There are approximately 600,000 people in the US who are living with TD—65% of them have not been diagnosed.

Study results indicate that switching from intravenous to subcutaneous vedolizumab in patients with IBD appears to be safe and effective.